Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users

Research output: Contribution to journalArticle

Abstract

This study compared the efficacy of buprenorphine to methadone for decreasing cocaine use in patients with combined opioid and cocaine use. Participants (n=51) were enrolled in a 26-week treatment program and randomly assigned to either buprenorphine or methadone. Dosing was double-blind and double-dummy. Patients were stabilized on either 8 mg sublingual buprenorphine or 50 mg oral methadone, with dose increases given in response to continued illicit cocaine use or opioid use through week 16 of treatment. Maximum doses possible were 16 mg buprenorphine and 90 mg methadone. Average doses achieved were 11.2 mg buprenorphine and 66.6 mg methadone; 49% of the patients received the maximum doses possible. Urine samples were collected three times per week, and there was no significant difference in the rate of cocaine positive urines for the intent-to-treat sample (69% for buprenorphine versus 63% for methadone). For patients who remained in treatment through the flexible dosing period (n=28), there were significant decreases in cocaine positive urines over time (P

Original languageEnglish (US)
Pages (from-to)401-406
Number of pages6
JournalPsychopharmacology
Volume116
Issue number4
DOIs
StatePublished - Dec 1994

Fingerprint

Buprenorphine
Methadone
Cocaine
Opioid Analgesics
Urine
Therapeutics

Keywords

  • Buprenorphine
  • Cocaine
  • Heroin
  • Methadone
  • Opioids

ASJC Scopus subject areas

  • Pharmacology

Cite this

Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. / Strain, Eric C; Stitzer, Maxine L; Liebson, Ira A.; Bigelow, George.

In: Psychopharmacology, Vol. 116, No. 4, 12.1994, p. 401-406.

Research output: Contribution to journalArticle

@article{4792460456e94b9194c718c21d65cd32,
title = "Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users",
abstract = "This study compared the efficacy of buprenorphine to methadone for decreasing cocaine use in patients with combined opioid and cocaine use. Participants (n=51) were enrolled in a 26-week treatment program and randomly assigned to either buprenorphine or methadone. Dosing was double-blind and double-dummy. Patients were stabilized on either 8 mg sublingual buprenorphine or 50 mg oral methadone, with dose increases given in response to continued illicit cocaine use or opioid use through week 16 of treatment. Maximum doses possible were 16 mg buprenorphine and 90 mg methadone. Average doses achieved were 11.2 mg buprenorphine and 66.6 mg methadone; 49{\%} of the patients received the maximum doses possible. Urine samples were collected three times per week, and there was no significant difference in the rate of cocaine positive urines for the intent-to-treat sample (69{\%} for buprenorphine versus 63{\%} for methadone). For patients who remained in treatment through the flexible dosing period (n=28), there were significant decreases in cocaine positive urines over time (P",
keywords = "Buprenorphine, Cocaine, Heroin, Methadone, Opioids",
author = "Strain, {Eric C} and Stitzer, {Maxine L} and Liebson, {Ira A.} and George Bigelow",
year = "1994",
month = "12",
doi = "10.1007/BF02247469",
language = "English (US)",
volume = "116",
pages = "401--406",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users

AU - Strain, Eric C

AU - Stitzer, Maxine L

AU - Liebson, Ira A.

AU - Bigelow, George

PY - 1994/12

Y1 - 1994/12

N2 - This study compared the efficacy of buprenorphine to methadone for decreasing cocaine use in patients with combined opioid and cocaine use. Participants (n=51) were enrolled in a 26-week treatment program and randomly assigned to either buprenorphine or methadone. Dosing was double-blind and double-dummy. Patients were stabilized on either 8 mg sublingual buprenorphine or 50 mg oral methadone, with dose increases given in response to continued illicit cocaine use or opioid use through week 16 of treatment. Maximum doses possible were 16 mg buprenorphine and 90 mg methadone. Average doses achieved were 11.2 mg buprenorphine and 66.6 mg methadone; 49% of the patients received the maximum doses possible. Urine samples were collected three times per week, and there was no significant difference in the rate of cocaine positive urines for the intent-to-treat sample (69% for buprenorphine versus 63% for methadone). For patients who remained in treatment through the flexible dosing period (n=28), there were significant decreases in cocaine positive urines over time (P

AB - This study compared the efficacy of buprenorphine to methadone for decreasing cocaine use in patients with combined opioid and cocaine use. Participants (n=51) were enrolled in a 26-week treatment program and randomly assigned to either buprenorphine or methadone. Dosing was double-blind and double-dummy. Patients were stabilized on either 8 mg sublingual buprenorphine or 50 mg oral methadone, with dose increases given in response to continued illicit cocaine use or opioid use through week 16 of treatment. Maximum doses possible were 16 mg buprenorphine and 90 mg methadone. Average doses achieved were 11.2 mg buprenorphine and 66.6 mg methadone; 49% of the patients received the maximum doses possible. Urine samples were collected three times per week, and there was no significant difference in the rate of cocaine positive urines for the intent-to-treat sample (69% for buprenorphine versus 63% for methadone). For patients who remained in treatment through the flexible dosing period (n=28), there were significant decreases in cocaine positive urines over time (P

KW - Buprenorphine

KW - Cocaine

KW - Heroin

KW - Methadone

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=0028097132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028097132&partnerID=8YFLogxK

U2 - 10.1007/BF02247469

DO - 10.1007/BF02247469

M3 - Article

C2 - 7701040

AN - SCOPUS:0028097132

VL - 116

SP - 401

EP - 406

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -